Breaking News Instant updates and real-time market news.

STJ

Acquired by ABT

$79.44

1.78 (2.29%)

, ABT

Abbott

$41.17

0.58 (1.43%)

07:17
10/19/16
10/19
07:17
10/19/16
07:17

St. Jude Medical says 'excited' about Abbott transaction

Commenting on the company's financial results, St. Jude Medical (STJ) President and CEO, Michael T. Rousseau said, "Third quarter results continue to confirm that our innovation based growth strategy is on track. As we continue to establish ourselves as the global technology leader in our markets, our focus is on bringing new technology to patients in the fourth quarter and throughout 2017 that will elevate current standards of care while reducing the cost of healthcare. We also remain excited about the Abbott (ABT) transaction, which we continue to expect to close in the fourth quarter of 2016." As previously announced, St. Jude Medical has changed its sales reporting to more closely align with how the company manages the business in five key areas: atrial fibrillation, heart failure, neuromodulation, cardiovascular and traditional cardiac rhythm management. AF product sales for the third quarter totaled $316 million, a 14 percent increase on a reported basis and a 12 percent increase on a constant currency basis compared to the prior year quarter. HF product sales, which include cardiac resynchronization therapy products, HeartMate ventricular assist devices and the CardioMEMS HF System, totaled $351 million for the third quarter, a 46 percent increase compared to the prior year quarter. St. Jude Medical sales of neuromodulation products were $141 million in the third quarter of 2016, a 17 percent increase on both a reported and constant currency basis compared to the prior year quarter. Total cardiovascular sales were $313 million for the third quarter of 2016, an increase of 8 percent compared to the prior year quarter. Total CRM sales, which include single and dual chamber implantable cardioverter defibrillator and pacemaker products, were $378 million for the third quarter of 2016, a 7 percent decline on both a reported and constant currency basis compared to the third quarter of 2015.

STJ

Acquired by ABT

$79.44

1.78 (2.29%)

ABT

Abbott

$41.17

0.58 (1.43%)

  • 19

    Oct

  • 19

    Oct

  • 21

    Oct

  • 26

    Oct

  • 06

    Nov

STJ Acquired by ABT
$79.44

1.78 (2.29%)

10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
ABT Abbott
$41.17

0.58 (1.43%)

09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.

TODAY'S FREE FLY STORIES

NUE

Nucor

$62.83

1.97 (3.24%)

15:46
02/27/17
02/27
15:46
02/27/17
15:46
Options
Nucor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKA

Roka Bioscience

$4.26

-0.18 (-4.05%)

15:44
02/27/17
02/27
15:44
02/27/17
15:44
Conference/Events
Roka Bioscience to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 29

    Mar

TESS

TESSCO

$14.05

-0.3 (-2.09%)

15:43
02/27/17
02/27
15:43
02/27/17
15:43
Hot Stocks
TESSCO signs deal with GEAR4 as exclusive U.S. distributor »

TESSCO Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LJPC

La Jolla

$19.87

1.65 (9.06%)

15:42
02/27/17
02/27
15:42
02/27/17
15:42
Recommendations
La Jolla analyst commentary  »

La Jolla price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

CUR

Neuralstem

$3.86

0.16 (4.32%)

15:36
02/27/17
02/27
15:36
02/27/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Neuralstem »

Tianjin Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.46

0.49 (1.53%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Options
58.com options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NURO

NeuroMetrix

$0.63

-0.0317 (-4.79%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Conference/Events
NeuroMetrix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CGI

Celadon Group

$8.55

0.45 (5.56%)

, USAK

USA Truck

$9.00

0.14 (1.58%)

15:33
02/27/17
02/27
15:33
02/27/17
15:33
Hot Stocks
Celadon, USA Truck called best M&A targets as truckers seen consolidating »

Stephens argued that amid…

CGI

Celadon Group

$8.55

0.45 (5.56%)

USAK

USA Truck

$9.00

0.14 (1.58%)

HTLD

Heartland Express

$20.64

0.2 (0.98%)

KNX

Knight Transportation

$32.70

0.55 (1.71%)

SWFT

Swift Transportation

$22.09

0.35 (1.61%)

CVTI

Covenant Transportation

$20.06

0.05 (0.25%)

MRTN

Marten Transport

WERN

Werner

$27.80

0.45 (1.65%)

XPO

XPO Logistics

$51.41

1.01 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 02

    May

GLD

SPDR Gold Trust

$119.45

-0.25 (-0.21%)

15:32
02/27/17
02/27
15:32
02/27/17
15:32
Options
Aggressive short-term call spread in the SPDR Gold Fund »

Aggressive short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$6.73

0.15 (2.28%)

, EQT

EQT Corporation

$60.73

0.785 (1.31%)

15:31
02/27/17
02/27
15:31
02/27/17
15:31
Hot Stocks
Stone Energy announces close of sale of Appalachia properties »

Stone Energy (SGY)…

SGY

Stone Energy

$6.73

0.15 (2.28%)

EQT

EQT Corporation

$60.73

0.785 (1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

15:20
02/27/17
02/27
15:20
02/27/17
15:20
Options
Exelixis options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

$NSD

NASDAQ Market Internals

15:17
02/27/17
02/27
15:17
02/27/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/27/17
02/27
15:16
02/27/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$29.94

-0.25 (-0.83%)

15:14
02/27/17
02/27
15:14
02/27/17
15:14
Periodicals
GE sales process for Industrial Solutions may start in March, Bloomberg says »

Amid its continuing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

VIP

VimpelCom

$4.30

-0.04 (-0.92%)

15:11
02/27/17
02/27
15:11
02/27/17
15:11
Options
Higher option volume in Vimpel driven by poste-earnings puts »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAC

Marriott Vacations

$96.51

-2.39 (-2.42%)

15:09
02/27/17
02/27
15:09
02/27/17
15:09
Conference/Events
Marriott Vacations management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TGT

Target

$66.95

0.435 (0.65%)

, AZO

AutoZone

$734.44

1.685 (0.23%)

15:06
02/27/17
02/27
15:06
02/27/17
15:06
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$66.95

0.435 (0.65%)

AZO

AutoZone

$734.44

1.685 (0.23%)

DPZ

Domino's Pizza

$185.90

-0.378 (-0.20%)

VRX

Valeant

$16.73

0.5499 (3.40%)

PAH

Platform Specialty Products

$13.19

0.14 (1.07%)

ENDP

Endo

$13.15

-0.24 (-1.79%)

DDD

3D Systems

$17.04

0.55 (3.34%)

SEAS

SeaWorld

$18.66

0.035 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

, WDAY

Workday

$90.92

1.26 (1.41%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Earnings
Notable companies reporting after market close »

Notable companies…

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

WDAY

Workday

$90.92

1.26 (1.41%)

PRGO

Perrigo

$84.39

-0.04 (-0.05%)

ALB

Albemarle

$92.74

-0.19 (-0.20%)

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

RSPP

RSP Permian

$40.77

0.88 (2.21%)

FTR

Frontier Communications

$3.37

-0.02 (-0.59%)

CST

CST Brands

$48.37

0.02 (0.04%)

THC

Tenet

$22.36

0.365 (1.66%)

HTZ

Hertz

$19.86

-0.11 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 20

    Mar

  • 21

    Mar

HTZ

Hertz

$19.87

-0.105 (-0.53%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Options
Hertz options imply 18.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

15:00
02/27/17
02/27
15:00
02/27/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MNK

Mallinckrodt

$54.42

1.04 (1.95%)

14:57
02/27/17
02/27
14:57
02/27/17
14:57
Conference/Events
Mallinckrodt management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 03

    Mar

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Acquired by ENB

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Acquired by ENB

ENB

Enbridge

$42.05

0.705 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

DDS

Dillard's

$56.99

-0.01 (-0.02%)

, ISIL

Intersil

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$56.99

-0.01 (-0.02%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRK

WestRock

$53.69

0.26 (0.49%)

14:54
02/27/17
02/27
14:54
02/27/17
14:54
Conference/Events
WestRock management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GIG

GigPeak

$3.10

0.03 (0.98%)

14:52
02/27/17
02/27
14:52
02/27/17
14:52
Hot Stocks
Gardner Lewis reports new 8.6% stake in GigPeak »

Shares of GigPeak spiked…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 05

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.